Theravance Biopharma, Inc.
TBPHHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Theravance Biopharma, Inc. (TBPH) is listed under Biotechnology. Valued at $821.8M, TBPH is a small-cap name in its sector. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA).
Market Cap
$821.8M
Beta
0.19
P/E (TTM)
7.15
P/E (Fwd)
12.70
EPS (TTM)
$2.23
EPS (Fwd)
$1.25
ROE
50.2%
ROA
0.8%
Cash
$394.7M
Total Debt
$40.5M
Free CF
$22.5M
52W Change
43.4%
Annual Financials
Cash vs Debt
With $394.7M in cash and $40.5M in debt, TBPH maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $22.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 50.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 0.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $51.3M (2022) to $107.5M (2025), reflecting a 109% increase over the period.
The relatively low beta of 0.19 suggests TBPH is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, TBPH has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing TBPH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.